Cabbacis Expands Global Patent Portfolio with New Vaporizer Innovation
Cabbacis Receives New U.S. Patent for Innovative Vaporizer Pods
Cabbacis Now Holds Patents in 31 Countries for its Vaporizer Pods
Cabbacis (CABI), a U.S.-licensed manufacturer focused on harm-reduction products, shares exciting news that the United States Patent and Trademark Office has granted a patent for its vaporizer pods designed for oral electronic vaporizers.
Details of the U.S. Patent No. 12,349,724
This specific patent, numbered 12,349,724, encompasses ten claims related to vaporizer pods incorporating at least 5 mg of reconstituted tobacco and 5 mg of hemp. Furthermore, it covers reduced-nicotine reconstituted tobacco mixed with hemp. These innovative pods are expected to enhance user experience, particularly when used with closed-end electronic vaporizers such as popular heat-not-burn models like IQOS and Ploom.
Benefits of the Newly Patented Vaporizer Pods
The vaporizer pods granted under the new patent will enable consumers to enjoy a distinctive and pleasurable taste profile thanks to the blend of conventional-nicotine tobacco and hemp. This contrasts with existing products that do not include hemp, providing users with a new flavor experience.
Existing Intellectual Property and Market Reach
Cabbacis also possesses prior U.S. patents covering vaporizer pods that combine tobacco and hemp, namely patents 10,777,091 and 10,973,255. This broad patent portfolio bolsters their strong position in the industry as the Company continues to innovate.
Advancements in Harm Reduction Products
The patented reduced-nicotine iBlend™ vaporizer pods and cigarettes in development are designed to support consumers in reducing their tobacco use. The iBlend™ cigarettes are particularly noteworthy, containing around 95 percent less nicotine compared to traditional brands. Cabbacis is extending its reach with these products across major tobacco markets including the United States, Europe, China, Brazil, and Japan.
Remarks from the CEO
Joseph Pandolfino, the Chief Executive Officer of Cabbacis, expressed excitement regarding the acquisition of this new patent. He stated, "This strengthens our already robust intellectual property position and ensures that our innovations are protected across more than 30 countries. Together with our existing patents, this coverage comprehensively addresses various blends of both conventional-nicotine and reduced-nicotine tobacco with hemp in vaporizer products."
About Cabbacis
Cabbacis (CABI) is dedicated to pioneering products that aim to reduce tobacco-related harm. Their innovative iBlend™ line is aimed at the global community of smokers, seeking alternatives that combine reduced-nicotine tobacco with non-intoxicating hemp. This dual approach allows users to transition away from traditional smoking and vaping practices while still enjoying their preferences.
Research and Development Efforts
In recent clinical studies, iBlend™ products received high satisfaction ratings, significantly alleviating cravings for conventional cigarettes. Furthermore, Cabbacis plans to introduce new reduced-nicotine cigarettes and flavored vaporizer products to meet diverse consumer needs.
Global Patent Strategy
The company’s patent portfolio comprises 35 issued patents and various pending applications worldwide, encompassing markets where a significant portion of the world's smokers reside. Cabbacis maintains seven U.S. patents and aims to enhance its offerings in tobacco harm reduction products.
Investor Relations Contact
Lucas A. Zimmerman
Managing Director,
MZ Group - MZ North America
(949) 259-4987
CABI@mzgroup.us
www.mzgroup.us
Frequently Asked Questions
What is the significance of the U.S. Patent No. 12,349,724?
This patent secures the rights to vaporizer pods using blends of traditional tobacco and hemp, reflecting Cabbacis' commitment to innovative harm-reduction products.
How does Cabbacis's vaporizer pod differ from others?
The pods incorporate hemp, providing a unique flavor and sensory experience compared to other offerings that solely use conventional tobacco.
What does Cabbacis aim to achieve with reduced-nicotine products?
These products aim to assist users in smoking less or transitioning to less harmful alternatives, ultimately supporting cessation efforts.
In which countries is Cabbacis patent protected?
Cabbacis holds patents in over 30 countries, covering key markets in the global tobacco industry.
What customer feedback have Cabbacis products received?
Clinical trials indicate high satisfaction levels among users, particularly with the iBlend™ reduced-nicotine cigarettes, which significantly reduce cravings.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.